Agreement of Joint FilingJoint Filing Agreement • July 3rd, 2007 • Taro Pharmaceutical Industries LTD • Pharmaceutical preparations
The undersigned hereby agree that the Statement on Schedule 13D, dated July 2, 2007 (“Statement”), with respect to the Ordinary Shares par value NIS 0.0001 per share, of Taro Pharmaceutical Industries Ltd. is, and any amendments thereto executed by each of us shall be, filed on behalf of each of us pursuant to and in accordance with the provisions of Rule 13d 1(k)(1) under the Securities and Exchange Act of 1934, as amended, and that this Agreement shall be included as an Exhibit to the Schedule 13D and each such amendment. Each of the undersigned agrees to be responsible for the timely filing of the Schedule 13D and any amendments thereto, and for the completeness and accuracy of the information concerning itself contained therein. This Agreement may be executed in any number of counterparts, all of which taken together shall constitute one and the same instrument.
indemnification agreementIndemnification Agreement • July 25th, 2022 • Taro Pharmaceutical Industries LTD • Pharmaceutical preparations
THIS INDEMNIFICATION AGREEMENT (the “Agreement”), dated as of January 1, 2018, is entered into by and between Taro Pharmaceutical Industries Ltd., an Israeli company whose address is 14 Hakitor St., Haifa Bay 26110, Israel (the “Company”), and ____________, a ________ of the Company whose address is ______________________ (the “Indemnitee”).
AGREEMENT OF MERGERAgreement of Merger • January 17th, 2024 • Taro Pharmaceutical Industries LTD • Pharmaceutical preparations
This Agreement of Merger is made and entered into as of January 17, 2024 by and among Sun Pharmaceutical Industries Ltd., a corporation organized under the laws of India (“Parent”), Alkaloida Chemical Company ZRT (f/k/a Alkaloida Chemical Company Exclusive Group Limited) (“Alkaloida”), a corporation organized under the laws of Hungary and under the control of Parent, The Taro Development Corporation, a corporation organized under the laws of New York and under the control of Parent (“TDC”), Sun Pharma Holdings, a corporation organized under the laws of Mauritius and a direct wholly owned subsidiary of Parent (“SPH”), Libra Merger Ltd., an Israeli company under the control of Parent and a direct wholly owned subsidiary of Alkaloida, TDC and SPH (“Merger Sub”), and Taro Pharmaceutical Industries Ltd., an Israeli company (the “Company”). Certain capitalized terms used but not defined in this Agreement are defined in Exhibit A hereto.
AGREEMENT AND PLAN OF MERGER by and among SUN PHARMACEUTICAL INDUSTRIES, INC., SUN DEVELOPMENT CORPORATION I, THE TARO DEVELOPMENT CORPORATION, BARRIE LEVITT, and DAN MOROS Dated as of May 18, 2007Merger Agreement • July 3rd, 2007 • Taro Pharmaceutical Industries LTD • Pharmaceutical preparations • New York
This Agreement and Plan of Merger (this “Agreement”) is made and entered into as of May 18, 2007, by and among SUN PHARMACEUTICAL INDUSTRIES, INC., a Michigan corporation (“Parent”), SUN DEVELOPMENT CORPORATION I, a New York corporation and a wholly-owned subsidiary of Parent (“Merger Sub”), THE TARO DEVELOPMENT CORPORATION, a New York corporation (the “Company”), BARRIE LEVITT (“Levitt”) and DANIEL MOROS (“Moros”).
LOAN AGREEMENT Made and entered into in Tel Aviv as of May 20, 2003Loan Agreement • June 29th, 2004 • Taro Pharmaceutical Industries LTD • Pharmaceutical preparations
OPTION LETTER AGREEMENTOption Letter Agreement • July 3rd, 2007 • Taro Pharmaceutical Industries LTD • Pharmaceutical preparations
Reference is made to the Share Purchase Agreement (the “SPA”), dated May 18, 2007 (the “SPA”), between Taro Pharmaceutical Industries Ltd. (the “Company”) and Alkaloida Chemical Company Exclusive Group Ltd. (the “Purchaser”). Capitalized terms not defined herein shall have the same meanings set forth in the SPA.
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • July 3rd, 2007 • Taro Pharmaceutical Industries LTD • Pharmaceutical preparations • New York
REGISTRATION RIGHTS AGREEMENT, dated as of May 18, 2007 (this “Agreement”), by and among Taro Pharmaceutical Industries Ltd., a company organized under the laws of the State of Israel (the “Company”) and Alkaloida Chemical Company Exclusive Group Ltd. (the “Investor”).
AGREEMENT OF MERGERMerger Agreement • August 13th, 2012 • Taro Pharmaceutical Industries LTD • Pharmaceutical preparations
This Agreement of Merger is made and entered into as of August 12, 2012 by and among Sun Pharmaceutical Industries Limited, a corporation organized under the laws of India (“Parent”), Alkaloida Chemical Company Exclusive Group Limited (“Alkaloida”), a corporation organized under the laws of Hungary and under the control of Parent, Aditya Acquisition Company Ltd., an Israeli company under the control of Parent and a direct wholly owned subsidiary of Alkaloida (“Merger Sub”), and Taro Pharmaceutical Industries Ltd., an Israeli company (the “Company”). Certain capitalized terms used but not defined in this Agreement are defined in Exhibit A hereto.
Second Joinder Agreement Dated as of October 18, 2011Joinder Agreement • October 18th, 2011 • Taro Pharmaceutical Industries LTD • Pharmaceutical preparations
The undersigned hereby agrees to join as a party to that certain Agreement of Joint Filing, dated as of July 2, 2007, among Sun Pharmaceutical Industries Ltd., Sun Pharma Global, Inc. and Alkaloida Chemical Company Exclusive Group Ltd., joined by Sun Pharmaeutical Industries, Inc. in that certain Joinder Agreement, dated as of September 24, 2010.
Joinder AgreementJoinder Agreement • September 24th, 2010 • Taro Pharmaceutical Industries LTD • Pharmaceutical preparations
The undersigned hereby agrees to join as a party to that certain Agreement of Joint Filing, dated as of July 2, 2007, among Sun Pharmaceutical Industries Ltd., Sun Pharma Global, Inc. and Alkaloida Chemical Company Exclusive Group Ltd.
INDEMNIFICATION AGREEMENTIndemnification Agreement • April 7th, 2011 • Taro Pharmaceutical Industries LTD • Pharmaceutical preparations
THIS INDEMNIFICATION AGREEMENT (the “Agreement”), dated as of __________, 20__, is entered into by and between Taro Pharmaceutical Industries Ltd., an Israeli company whose address is Euro Park, Italy House, Yakum 60972, Israel (the “Company”), and _______________, a director of the Company whose address is ________________ (the “Indemnitee”).
